You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Preclinical Development of a Novel Small Molecule Drug for Sepsis

    SBC: THERASOURCE, LLC            Topic: 300

    PROJECT DESCRIPTIONThis STTR Phase I proposal is intended to demonstrate the feasibility of developing tanshinone small molecule analogTSAas an effective and safe small molecule therapy for patients with sepsis and septic shockIn the USmore than one million people develop sepsis every yearYetno effective anti sepsis treatment exists other than antibiotics and supportive careWe have discovered that ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines

    SBC: VaxNewMO            Topic: NIAID

    PROJECT SUMMARY Pneumococcal pneumonia remains the leading cause of bacterial pneumonia in both children under years of age and adults over years of age The standard preventative therapy is the conjugate vaccine Prevnar which consists of an immunogenic carrier protein covalently attached to one of thirteen pneumococcal capsular polysaccharides Although Prevnar has significantly red ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Science Take-Out Kits for Environmental Health Education

    SBC: Science Take-Out, LLC            Topic: NIEHS

    ABSTRACT Nearlypercent of death and diseaseworldwideis linked to environmental factorsWHOthereforeit is critical that the general public has a basic understanding of how the environment affects their health and how they might protect themselves against environmental exposuresUnfortunatelyenvironmental health is typically covered minimallyif at allin secondary school classroomsMartinaand there are ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Discovery of Novel Drugs for Autism

    SBC: ASDDR, LLC            Topic: 101

    Summary The goal of this study is to discover novelmechanism based pharmacological intervention for autisma devastating neurodevelopmental disorder with no treatment currentlyGenetic sequencing has revealed extensive overlap in risk genes for autism and for cancermany of which are chromatin remodeling factors important for transcriptional regulationsuggesting the possibility of repurposing the ant ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. ErythroMer Nanoscale Bio Synthetic Red Cell Substitute

    SBC: KaloCyte Inc            Topic: NHLBI

    PROJECT SUMMARY There is need for an artificial oxygen O carrier to substitute for banked blood in settings where stored blood is unavailable pre hospital care transport austere environments undeveloped countries or undesirable transfusion risk exceeds benefit To address this need we developed ErythroMer EM a first in class nano cyte blood substitute EM is a deformable ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Enabling point of care molecular diagnostics by developing an adaptive PCR instrument and on demand kit reagents

    SBC: BIOVENTURES, INC            Topic: 172

    Because of its high sensitivity polymerase chain reaction PCR is the gold standard for the diagnosis of many infectious diseases but generally only implemented in well equipped laboratories One of the major roadblocks for expanding PCR to point of care markets is the lack of simple robust single tube PCR designs which preserve its laboratory based high sensitivity and specificity In this F ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. A novel product for tendinopathy treatment

    SBC: NEW YORK R & D CENTER FOR TRANSLATIONAL MEDICINE & THERAPEUTICS INC            Topic: NIA

    Project Summary This study aims to prove the concept and feasibility that TendonCure extracellular vesicles that contain signaling molecules i e exosomes secreted by mesenchymal stem cells i e tendon stem progenitor cells TSPCs or adipose derived stem cells ADSCs from individual patients donors cultured on a novel scaffold exert therapeutic efficacy on tendinopathy when injected into ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Microfabrication based Biomimetic Approach for In Vitro Red Blood Cell Maturation

    SBC: Simpore Inc.            Topic: NHLBI

    Abstract The overall goal of this proposal is to develop systems for efficient ex vivo maturation of functional human red blood cells RBCs which holds tremendous potential for addressing supply bottlenecks for delivering new therapeutic options to chronically transfused patients with severe alloimmunization and for novel strategies for delivering therapeutics via engineered RBCs No approaches ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Structure based optimization of a novel pharmacological chaperone therapy for MPSIIIC

    SBC: Phoenix Nest Inc.            Topic: NICHD

    PROJECT SUMMARY Lysosomal storage diseases LSD are rare inherited metabolic disorders caused by defects in the cellular catabolic system Mucopolysaccharidosis Type IIIC MPS IIIC or Sanfilippo disease type C is one such LSD that is caused by deficiency of the enzyme heparan sulfate acetyl CoA glucosaminide N acetyltransferase HGSNAT essential for degradation of heparan sulfate a repeati ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Develop a new cisplatin based drug combination with reduced ototoxicity

    SBC: GATEWAY BIOTECHNOLOGY, INC.            Topic: NIDCD

    PROJECT SUMMARY In spite of recent new drug developments platinum based drugs such as cisplatin are still widely used to treat solid organ malignancies Besides its limited efficacy serious side effects have been associated with the use of cisplatin such as bilateral and irreversible hearing loss In the cochlea cisplatin can trigger the production of reactive oxygen species and activate sev ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government